argenx
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after announcing the acq...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span ...
Latest News
8 days ago · fool.com
3 Reasons Argenx Could Be a Top Biotech Stock for the Next DecadeArgenx's Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030. The biotech is solidly profitable, with Q3 revenue up 54% and $3.7 billion in cash to fund growth.
8 days ago · globenewswire.com
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation MedicinesArgenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion
12 days ago · zacks.com
Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGXInvestors should consider buying resurgent healthcare and biotech stocks amid the AI selloff. Today, we are digging into why it might be time to buy biopharmaceutical stock Argenx (ARGX).
14 days ago · globenewswire.com
argenx to Present at Upcoming Investor ConferencesNovember 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference. Fireside chat on Tuesday, November 10 at 2:00 p.m.
25 days ago · fool.com
argenx: 3 Key Takeaways for Long-Term InvestorsProduct net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.
26 days ago · seekingalpha.com
argenx SE (ARGX) Q3 2026 Earnings Call Transcriptargenx SE ( ARGX ) Q3 2026 Earnings Call October 22, 2026 8:30 AM EDT Company Participants Beth DelGiacco Karen Massey - CEO & Executive Director Karl Gubitz - Chief Financial Officer Sandrine Piret-Gerard - Chief Commercialization Officer Luc Truyen - Chief Medical Officer Conference Call Participants Daniel Giraldo Perez - BofA Securities, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Victor Floch - BNP Paribas, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Yaron Werber - TD Cowen, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Jing Deng Sean Laaman - Morgan Stanley, Research Division Sophia Graeff Buhl Nielsen - JPMorgan Chase & Co, Research Division Luca Issi - RBC Capital Markets, Research Division Douglas Tsao - H.C.
26 days ago · marketbeat.com
What argenex (ARGX) Said on Its Q3 Earnings Callargenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chronic inflammatory demyelinating polyneuropathy, or CIDP, continued to support demand for VYVGART.
1 month ago · globenewswire.com
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.
1 month ago · zacks.com
argenx Meets Primary Endpoint in Phase II Celiac Disease StudyARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
1 month ago · zacks.com
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Studyargenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ARGX